Recursion Pharmaceuticals (RXRX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.22

Estimate

-$0.23

Surprise

+3.9%

Revenue (period 2026-09-30)

$18.6M

Score today

4.6/10

Revenue source: xbrl.

Recursion Pharmaceuticals (RXRX) reported a narrower loss than forecast — adjusted EPS of -$0.22 against the -$0.23 estimate (a 3.9% beat on a still-unprofitable quarter).

• Recursion Announces Positive Phase 2 Data for REC-4881 in TUPELO Trial — fiscal.ai, 2026-11-02
• Recursion Reports Third Quarter 2026 Financial Results and Business Updates — fiscal.ai, 2026-11-02
• Recursion Appoints Fred Hassan as Chair of the Board — fiscal.ai, 2026-11-02

TrendMatrix currently rates RXRX Sell at 4.6/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a +11.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.83

Price target

$6.37

Stop

$3.56

Upside to target

+66.3%

Reward-to-risk

4.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.29B

P/E (fwd)

-4.4

52-week range

$2.77–$5.76

Off 52-week high

33.5%

RSI (14)

50

Volume vs avg

0.77×

Score today

4.6/10